Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Avandia, Actos To Accelerate Market Growth With Rezulin's Withdrawal

Executive Summary

The removal of Warner-Lambert's Rezulin will boost sales of the two newer antidiabetic "glitazones," SmithKline Beecham/Bristol-Myers Squibb's Avandia and Lilly/Takeda's Actos.

You may also be interested in...



Liver Toxicity Guidance Urges Sponsors To Include Risky Patients In Trials

FDA's recent draft guidance on drug-induced liver injury recommends drug developers enroll patients with preexisting liver disease in at least Phase III clinical trials, especially if the drug might eventually be used in such patients.

Liver Toxicity Guidance Urges Sponsors To Include Risky Patients In Trials

FDA's recent draft guidance on drug-induced liver injury recommends drug developers enroll patients with preexisting liver disease in at least Phase III clinical trials, especially if the drug might eventually be used in such patients.

FDA Is Waiting On Internal Analysis Of Avandia Cardiovascular Safety Signal

FDA is not taking immediate regulatory action on an observed cardiovascular signal for GlaxoSmithKline's Avandia, as the agency feels the current labeling is sufficient until its own analysis of emerging safety data for the type 2 diabetes therapy is completed

Related Content

UsernamePublicRestriction

Register

PS035780

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel